Lineage Cell Therapeutics (LCTX) Change in Receivables (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Change in Receivables of -$154000.0 for Q1 2026, up 63.68% on a YoY basis from -$94086.5 in Q1 2025, and down 118.62% quarter-over-quarter from $827000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Change in Receivables (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Change in Receivables for 17 years, with the latest figure at -$154000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 63.68% year-over-year to -$154000.0; the trailing twelve-month figure through Mar 2026 stood at $586000.0 (up 324.64% YoY), and the FY2025 full-year result was $316000.0, up 398.11% from the prior year.
- Change in Receivables for Q1 2026 stood at -$154000.0, down from $827000.0 in the prior quarter.
- The five-year high for Change in Receivables was $827000.0 in Q4 2025, with the low at -$50.3 million in Q1 2022.
- Historically, Change in Receivables has averaged -$2.9 million across 5 years, with a median of -$6000.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Receivables slumped 37374.81% — and 2024, when it surged 2916.67%.
- Lineage Cell Therapeutics' Change in Receivables stood at -$108000.0 in 2022, then jumped by 382.41% to $305000.0 in 2023, then slipped by 23.61% to $233000.0 in 2024, then soared by 254.94% to $827000.0 in 2025, then sank by 118.62% to -$154000.0 in 2026.
- The last three Change in Receivables figures came in at -$154000.0 (Q1 2026), $827000.0 (Q4 2025), and -$130000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -154,000.00 |
| Mar 31, 2026 | -154,000.00 |
| Dec 31, 2025 | 827,000.00 |
| Dec 31, 2025 | 827,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Mar 31, 2025 | -424,000.00 |
| Mar 31, 2025 | -424,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Mar 31, 2024 | -668,000.00 |
| Mar 31, 2024 | -668,000.00 |
| Dec 31, 2023 | 305,000.00 |
| Dec 31, 2023 | 305,000.00 |